Biologic monotherapy in the treatment of rheumatoid arthritis

Abstract

Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data.

Retention rates of adalimumab, etanercept and infliximab as first‐line biotherapy agent for rheumatoid arthritis patients in daily practice ‐ Auvergne experience

“…We did not find any difference among the three anti‐TNFs, and this was also revealed by other studies . Response to anti‐TNF treatment was higher in patients receiving concomitant MTX treatment, and this confirms, in real life, the data from therapeutic trials and registries . The male gender was sometimes a predictive factor of improved response, but this was neither the case in our study nor in Kristensen's study .…”

Retracted: miR‐145 eliminates lipopolysaccharides‐induced inflammatory injury in human fibroblast‐like synoviocyte MH7A cells

“…1 Joint synovial chronic inflammation leads to the formation of pannus, which destroys cartilage bone and surrounding tissues. 1 Joint synovial chronic inflammation leads to the formation of pannus, which destroys cartilage bone and surrounding tissues.…”

“…Rheumatoid arthritis (RA) is an antoimmune connective tissue disease characterized by systemic inflammation and synovial inflammation. 1 Joint synovial chronic inflammation leads to the formation of pannus, which destroys cartilage bone and surrounding tissues. Approximately 1% of the world population suffers from this disease, and it puts a tremendous economic burden on the society.…”

Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study

“…On the other hand, biological DMARDs like etanercept, adalimumab etc. showed higher efficacy, however it's use is limited due to parenteral administration, high cost and accessibility etc [3,4]. To overcome these drawbacks, Janus kinase (JAK)/signal transducer and activator of the transcription (STAT) signal pathway has been identified as one of the new therapeutic targets to treat rheumatoid arthritis.…”